Media Contact:
Pam Lord
Porter Novelli Life Sciences
619-849-6003
plord@pnlifesciences.com
|
|
NEREUS PHARMACEUTICALS APPOINTS DR. CHARLES WHITE AS
CHIEF BUSINESS OFFICER
SAN DIEGO, Calif.,
June 28, 2006 - Nereus Pharmaceuticals, Inc., a pioneer in drug discovery and
development from marine microbial sources, today announced Charles
White, Ph.D., was appointed Chief Business Officer. Dr. White is
responsible for overall business leadership with a focus on
negotiating partnerships and licensing agreements with
pharmaceutical, biotech and academic collaborators.
- Dr. White's extensive experience in all aspects of business
development within the pharmaceutical industry makes him an
excellent addition to the Nereus team. He will lead our initiative
to establish partnerships to advance our clinical development
programs and alliances to capitalize on our drug discovery efforts,
said Kobi M. Sethna, President and CEO of Nereus Pharmaceuticals,
Inc.
Dr. White has over 25 years business development and marketing
experience in the industry, working most recently as Vice President
of Biotechnology Business Development at Organon, the pharmaceutical
business unit of Akzo Nobel. Prior to Organon, Dr. White was Vice
President at Diosynth, which recently merged with Organon, and was
responsible for business development and M&A activities. He also
held Vice President positions with Diosynth's predecessors, Corning
Bio and Covance Biotechnology Services, where he was head of
business development. Dr. White has also held various business
development and marketing positions with Medisorb Technologies and
E.I. DuPont Company. He received a Ph.D. in chemistry from the
University of California, Berkeley and a B.S. in chemistry from the
Georgia Institute of Technology.
About Nereus Pharmaceuticals, Inc.
Nereus Pharmaceuticals pursues untapped sources of chemical
diversity to discover and develop novel therapeutics. With unmatched
expertise in marine microbiology and integrated technologies to
identify and synthesize novel biologically active compounds, the
Company's two oncology drug candidates are in Phase I clinical
trials. NPI-2358, a tumor vascular disrupting agent, is being
evaluated for solid tumors, and proteasome inhibitor NPI-0052 is
being developed for solid tumors, lymphomas and multiple myeloma.
Nereus' discovery portfolio also includes additional drug candidates
for oncology, as well as infectious diseases and inflammation. The
Company is privately held and based in San Diego, California. For
more information, visit
www.nereuspharm.com.
###
Nereus Pharmaceuticals is a
registered trademark of Nereus Pharmaceuticals, Inc.
|
